The target of the study is a family of proteins that cancer cells exploit with devastating efficiency: the antiapoptotic Bcl-2 family. Apoptosis, or programmed cell death, is the body’s built-in quality control system, removing damaged, aged, or unwanted cells through two main routes, the mitochondrial intrinsic pathway and the extrinsic death receptor pathway. The intrinsic route is governed by the Bcl-2 protein family, which includes antiapoptotic members such as Bcl-2, Bcl-xL, Bcl-w, and Mcl-1, and proapoptotic players like Bax, Bak, and a suite of BH3-only proteins. When proapoptotic proteins oligomerize on the mitochondrial outer membrane, they trigger mitochondrial outer membrane permeabilization, releasing cytochrome c, assembling the apoptosome with Apaf-1, and activating the caspase enzymes that dismantle the cell. Antiapoptotic members act as guardians of the mitochondrial membrane, sequestering their proapoptotic relatives and preventing this point of no return.

Cancer cells frequently overexpress these antiapoptotic guardians, blocking the release of caspase-activating factors and thereby enhancing survival, proliferation, tumor progression, metastasis, angiogenesis, and drug resistance. This makes them attractive drug targets, particularly because they sit at the final, largely irreversible step of cell death, unlike upstream signaling pathways such as EGFR, PI3K, ALK, and BRAF, which tumors can bypass through compensatory mutations. Drugs like ABT-737, ABT-263, and venetoclax have demonstrated the therapeutic promise of this strategy, but resistance often emerges when other family members such as Mcl-1 or Bcl-xL are overexpressed. For this reason, the researchers selected obatoclax, a pan-Bcl-2 family inhibitor capable of targeting multiple antiapoptotic proteins simultaneously, as their reference compound rather than the more selective venetoclax.

The study, published in Results in Chemistry, cast a wide net across the plant kingdom. The team assembled a library of 698 bioactive phytocompounds drawn from eight medicinal plants with long histories of therapeutic use: Lycium barbarum, Asparagus racemosus, Curcuma longa, Acorus calamus, Moringa oleifera, Aristolochia indica, Taxus baccata, and Taxus brevifolia. These plants are rich sources of carotenoids, flavonols, polyphenols, flavonoids, sterols, alkaloids, and terpenoids, with documented antioxidant, antineoplastic, anti-inflammatory, and cytotoxic activities. Compound structures were retrieved from the NPASS, IMPPAT, and KNApSAcK databases, prepared with OpenBabel and Discovery Studio, and docked against crystal structures of Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 obtained from the Protein Data Bank using AutoDock Vina within the PyRx platform.

The docking results were striking. Among the 698 compounds screened, only three, diosgenin, friedelin, and roridin E, outperformed obatoclax across all four antiapoptotic proteins, and diosgenin emerged as the clear leader. It achieved binding energies of −9.0 kcal/mol against Bcl-2, −9.3 kcal/mol against Bcl-xL, −8.5 kcal/mol against Bcl-w, and −8.2 kcal/mol against Mcl-1, consistently surpassing the control compound. Ligand efficiency analysis, which normalizes binding affinity by molecular size, confirmed that diosgenin offered a favorable balance between potency and molecular complexity, whereas larger compounds like violaxanthin achieved respectable scores only through sheer size. Receptor preference margin analysis further revealed that diosgenin favors multiple homologous Bcl-2 family proteins rather than a single receptor, with a preference order of Bcl-xL, followed by Bcl-2, Bcl-w, and Mcl-1, echoing the broad-spectrum profile that makes obatoclax clinically interesting.

Structural analysis showed why diosgenin binds so effectively. The compound occupies the hydrophobic groove formed by the BH1, BH2, and BH3 domains, the very pocket that antiapoptotic proteins use to grip the BH3 regions of their proapoptotic targets. With Bcl-2, diosgenin formed eight hydrophobic contacts involving residues such as Met-115, Val-156, Ala-149, Leu-137, Phe-104, and Phe-112. With Bcl-w, it generated thirteen hydrophobic interactions plus a hydrogen bond through Arg-95, engaging aromatic residues Phe-102 and Trp-137. Residue contact fingerprint analysis showed that phenylalanine, tyrosine, and leucine residues were conserved contact points across 75 percent of the target proteins, indicating that van der Waals and hydrophobic forces drive the interaction, and that diosgenin partially mimics the binding pattern of obatoclax while also forging unique contacts of its own. Redocking of co-crystallized ligands produced root-mean-square deviations below 2 angstroms for all targets, validating the docking protocol.

To confirm that these interactions would hold up in a dynamic, physiological environment, the team ran 200-nanosecond molecular dynamics simulations with the AMBER14 force field in YASARA under near-physiological conditions. The diosgenin-Bcl-xL complex proved more stable than the obatoclax control, with lower root-mean-square deviation, while the other complexes remained comparably stable. Root-mean-square fluctuation, solvent-accessible surface area, and radius of gyration analyses all pointed to compact, stable complexes, with diosgenin generally producing tighter protein conformations than the control. Hydrogen bond analysis revealed that diosgenin maintained roughly three hydrogen bonds with Bcl-2, more than double the control’s average, and secondary structure analysis confirmed that all proteins retained their predominantly alpha-helical folds throughout the simulations. MM-PBSA binding free energy calculations reinforced the picture, showing diosgenin complexes with Bcl-2 and Bcl-xL achieving more favorable energies than the control.

Perhaps most compelling are the drug-likeness and safety predictions. Diosgenin satisfied both Lipinski’s Rule of Five and Veber’s rules, showed high gastrointestinal absorption, crossed the blood-brain barrier, and, critically, did not inhibit any of the key cytochrome P450 enzymes, whereas obatoclax was predicted to interfere with CYP1A2, CYP3A4, and CYP2C19, raising the specter of drug-drug interactions. Toxicity profiling with ProTox-3 found diosgenin inactive for neurotoxicity, mutagenicity, hepatotoxicity, nephrotoxicity, carcinogenicity, and cardiotoxicity, with only mild predicted immunotoxicity, and a predicted median lethal dose of 8000 mg/kg compared with obatoclax’s 3066 mg/kg. Density functional theory calculations added a quantum mechanical dimension, showing a HOMO-LUMO energy gap of 5.279 eV for diosgenin versus 3.224 eV for obatoclax and a molecular electrostatic potential map indicating greater electron density and nucleophilicity for the plant compound.

These computational findings align intriguingly with a growing body of experimental literature. Previous studies have shown that diosgenin suppresses proliferation and triggers caspase-driven apoptosis in skin squamous carcinoma cells through AKT and JNK signaling, overcomes TRAIL resistance in colon cancer cells by downregulating the p38 MAPK pathway and elevating death receptor DR5, and curbs the invasion of triple-negative breast cancer cells by suppressing Vav2 phosphorylation and Cdc42 activation. In animal models, intra-tumoral diosgenin treatment markedly suppressed breast cancer xenograft growth in mice, and the compound reduced azoxymethane-induced aberrant crypt foci in rat models of colorectal cancer. The new study adds a mechanistic explanation for these observations: by wedging into the hydrophobic groove of antiapoptotic Bcl-2 family proteins, diosgenin could liberate proapoptotic effectors, drive mitochondrial outer membrane permeabilization, and push cancer cells irreversibly toward apoptosis.

The authors are careful to note the limits of their work. Every result, from the docking scores to the ADMET predictions, rests on computational models that require laboratory confirmation, and further in vitro and in vivo studies will be essential to establish diosgenin’s efficacy, bioavailability, and off-target profile in living systems. Still, the convergence of strong binding across all four antiapoptotic targets, stable simulated complexes, clean pharmacokinetics, and an exceptional predicted safety margin positions this humble plant saponin, found in fenugreek, wild yam, and other traditional remedies, as a genuinely promising scaffold for the next generation of Bcl-2 family inhibitors. If experimental validation keeps pace, a compound known to ancient healers may yet find a place in the modern oncology clinic.

Subject of Research: Computational identification of the natural plant compound diosgenin as an inhibitor of antiapoptotic Bcl-2 family proteins for cancer therapy

Article Title: Computational discovery of natural product-based anti-cancer agents targeting antiapoptotic family proteins through bioinformatics approach

Article References: Bulbul, M. I. A., Khan, T., Sharid, M. A. G., Shuvo, M. N., Debnath, A. C., Ali, M. A., & Haque, M. A. (2026). Computational discovery of natural product-based anti-cancer agents targeting antiapoptotic family proteins through bioinformatics approach. Results in Chemistry, 30, Article 103804. https://doi.org/10.1016/j.rechem.2026.103804

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103804

Keywords: diosgenin, Bcl-2 family proteins, apoptosis, molecular docking, molecular dynamics simulation, natural products, cancer drug discovery, MM-PBSA, ADMET prediction, obatoclax, phytocompounds, in silico drug design

The study is predicated on the grim reality of HCC, which is the most prevalent form of liver cancer and a leading cause of cancer-related deaths worldwide. The prognosis for patients diagnosed with HCC remains poor, primarily due to late-stage presentations and limited therapeutic options. Identifying biomarkers that could predict outcomes and guide treatment strategies is of paramount importance. In this context, the researchers suspect that BCL2L12 may influence not just tumor development but also the body’s immune response to cancer.

BCL2L12, an anti-apoptotic protein, has garnered attention in recent years for its involvement in various cancers, including breast and lung cancer. However, its explicit role in HCC has remained largely underexplored until now. This research provides an in-depth analysis of how BCL2L12 modulates immune signaling pathways and its potential impact on tumor microenvironment dynamics. By examining tumor samples and correlating BCL2L12 expression with immune cell infiltration, the research team sought to uncover the protein’s influence on the immune landscape.

The findings indicate that elevated levels of BCL2L12 are associated with a profound alteration in the immune microenvironment surrounding HCC tumors. Specifically, tumors expressing higher BCL2L12 levels showed a reduced presence of cytotoxic T cells and an increased accumulation of regulatory T cells. This shift in immune cell populations suggests that BCL2L12 not only promotes cancer cell survival but may also actively suppress the body’s immune response against the tumor. Such insights are crucial for understanding how tumors evade immune surveillance, which is a hallmark of cancer progression.

Moreover, the research highlights the correlation between BCL2L12 expression and various immune checkpoint molecules. Immune checkpoints, like PD-1 and CTLA-4, are critical in regulating immune responses. The study found that BCL2L12 expression levels inversely correlated with the expression of these checkpoints, suggesting that tumors with high BCL2L12 may deter effective immune responses by upregulating these checkpoints. This discovery could have significant implications for immunotherapy approaches, as tumoral BCL2L12 levels might serve as a biomarker to predict patient response to treatments that target these immune checkpoints.

In addition to exploring the relationship between BCL2L12 and immune cells, the study also investigates the downstream signaling pathways activated by BCL2L12 in HCC. The research team discovered that BCL2L12 engages specific pathways that enhance tumor proliferation and survival. Understanding these molecular mechanisms is vital for devising novel therapeutic strategies that can specifically target BCL2L12 and disrupt its oncogenic functions. By elucidating the underlying pathways that BCL2L12 manipulates, researchers can identify potential drug targets to enhance treatment efficacy.

To contextualize their findings, the researchers also compared the BCL2L12 expression profiles of HCC patients with different clinical outcomes. Their analysis revealed a striking association between high BCL2L12 levels and poorer overall survival rates. This data underscores the potential of BCL2L12 as a prognostic biomarker for HCC, providing valuable information to guide clinical decision-making. Patients showing high BCL2L12 expression may benefit from intensified monitoring and more aggressive treatment regimes.

To translate their laboratory findings into clinical relevance, the researchers propose several future directions. Firstly, they suggest conducting larger scale studies to validate BCL2L12 as a biomarker across diverse patient populations. Additionally, they recommend exploring the therapeutic targeting of BCL2L12 as a novel approach to enhance the efficacy of existing cancer therapies. Given the challenging landscape of HCC management, such strategies could provide new avenues for improving patient outcomes.

Public engagement and raising awareness about the findings of this study are also emphasized. As the implications of BCL2L12 as both an oncogene and a modulator of immune status unfold, disseminating this knowledge can empower patients and healthcare providers alike. By understanding the molecular underpinnings of HCC, stakeholders can advocate for better screening, timely diagnosis, and more tailored treatment strategies.

In summary, the research conducted by Niu, Cao, Lian, and colleagues provides essential insights into the role of BCL2L12 in hepatocellular carcinoma. Their findings pinpoint the dual role of this protein in promoting malignancy while simultaneously manipulating the immune microenvironment. Such revelations significantly contribute to the growing body of knowledge surrounding HCC, setting the stage for future investigations aimed at improving survival rates for patients afflicted with this devastating disease. As the battle against cancer continues, studies like these are instrumental in uncovering critical mechanisms that can ultimately lead to more effective treatments.

In conclusion, the investigation into BCL2L12 and its association with immune status in HCC underscores the importance of interdisciplinary approaches in cancer research. By intertwining the fields of molecular oncology and immunology, researchers can develop a more robust understanding of cancer dynamics. This research not only enhances our comprehension of hepatocellular carcinoma but also lays the groundwork for innovative therapeutic strategies and improved patient prognostication going forward.

Subject of Research: The oncogenic role of BCL2L12 associated with immune status in the prognosis of hepatocellular carcinoma.

Article Title: The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.

Article References:
Niu, K., Cao, S., Lian, N. et al. The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma. Sci Nat 112, 92 (2025). https://doi.org/10.1007/s00114-025-02040-9

Image Credits: AI Generated

DOI: 26 November 2025

Keywords: BCL2L12, hepatocellular carcinoma, immune status, prognostic biomarker, cancer therapy, immune microenvironment.

Mitochondria, the cellular powerhouses, have long been recognized as gatekeepers of apoptosis, a programmed and tightly regulated form of cell death vital for organismal homeostasis. Central to this process is MOMP, which leads to the release of apoptogenic factors like cytochrome c, triggering downstream caspase activation. Traditionally, the Bcl-2 family proteins Puma and Bax have been regarded as crucial mediators facilitating MOMP by forming pores in the outer mitochondrial membrane. However, the latest observations suggest that p53 itself translocates into mitochondria and directly induces MOMP, bypassing the requirement for Puma and Bax altogether.

This paradigm shift stems from an in-depth analysis of mitochondrial membrane dynamics under stress conditions promoting p53 activation. Detailed experimental evidence reveals that mitochondrial localization of p53 compromises membrane integrity through mechanisms mechanistically distinct from the canonical actions of Bax and Puma. These findings imply that p53 harbors intrinsic properties enabling it to act as an effector molecule at the mitochondrial level, exerting a profound impact on mitochondrial architecture and function. Such a discovery underscores p53’s versatility beyond its nuclear transcriptional functions, highlighting a direct protein-protein or protein-lipid interaction interface within mitochondria.

Further technical scrutiny indicates that p53’s mitochondrial translocation is accompanied by conformational changes enhancing its interaction with cardiolipin, a phospholipid uniquely enriched in the inner mitochondrial membrane. This interplay is thought to destabilize the outer membrane matrix, precipitating membrane permeabilization without relying on Bax and Puma oligomerization. Moreover, p53’s mitochondrial engagement appears to severely perturb the mitochondrial membrane potential, undermining bioenergetic stability and precipitating a cascade of events culminating in apoptotic cell death.

Insights into the molecular choreography unveiled by this research carry significant implications for cancer biology. Given that p53 is frequently mutated or functionally inactivated in tumors, understanding its alternative modes of inducing apoptosis is pivotal. This mitochondrial-centric apoptosis pathway could represent a therapeutic target in p53-defective cancers where traditional nuclear-mediated apoptotic functions are compromised. Exploiting this pathway might enable the design of novel anti-cancer strategies that reactivate or mimic p53’s mitochondrial functions, restoring apoptotic susceptibility in resistant tumor cells.

Intriguingly, the editorial expression of concern outlined in the 2025 issue of Cell Research invites the scientific community to reexamine the dogma surrounding p53-regulated apoptosis. It acknowledges the robustness of data indicating mitochondrial membrane disruption driven by p53 independently of Puma and Bax but also calls for caution until further validation addresses outstanding mechanistic queries. Questions remain about the exact biochemical nature of p53’s mitochondrial interactions and the potential involvement of other, yet unidentified mitochondrial factors that could modulate or facilitate its MOMP-inducing capabilities.

Such complexities in understanding mitochondrial dynamics during apoptosis are not trivial. The mitochondrion is a multifaceted organelle, hosting diverse functions beyond ATP synthesis, including calcium homeostasis, reactive oxygen species (ROS) generation, and apoptotic signaling. Disruption of mitochondrial membrane integrity by p53 may funnel into various intersecting pathways, influencing not only cell death but also metabolic reprogramming and inflammatory responses. Therefore, dissecting this novel role of p53 could illuminate interconnected cellular stress responses relevant to degenerative diseases and immune regulation, expanding its significance beyond oncology.

On a structural level, future investigations are poised to leverage high-resolution imaging and biophysical assays to capture the transient conformations and interactions of p53 at the mitochondrial interface. Such endeavors may reveal whether p53 forms oligomeric assemblies analogous to Bax pores or employs alternative membrane-disruptive mechanisms, such as lipid remodeling or recruitment of mitochondrial fission/fusion machinery. These molecular insights will be critical for refining models of mitochondrial apoptosis and identifying points for pharmacological modulation.

Additionally, given the profound disruption of mitochondrial membrane integrity observed, there are implications for the release patterns and kinetics of mitochondrial pro-apoptotic factors. The involvement of p53 may accelerate or amplify cytochrome c and Smac/DIABLO release, creating potential feedback loops that amplify apoptotic signaling. Alternatively, p53-mediated disruption might trigger mitochondrial permeability transition pore (mPTP) opening, linking apoptosis with necrotic cell death pathways under certain contexts. Such nuanced crosstalk is a fertile ground for exploration.

The editorial also underscores the importance of rigorous experimental reproducibility and transparent reporting in high-impact research. The expression of concern reflects the journal’s commitment to scientific integrity, spotlighting areas where data interpretations require further substantiation or where alternative explanations should be tested. In doing so, it encourages open scientific dialogue and collaborative efforts to demystify p53’s mitochondrial roles.

Beyond the basic science implications, these findings resonate deeply with translational and clinical research pursuits. Targeting mitochondrial apoptosis pathways, particularly those modulated by p53, may enhance the efficacy of chemotherapy and radiotherapy, which exert cytotoxic stress partly through p53 activation. Furthermore, understanding whether different p53 isoforms or post-translational modifications influence mitochondrial translocation and membrane perturbation could refine patient stratification and personalized medicine approaches.

In summary, the revelations surrounding p53’s role in MOMP independent of Puma and Bax mark a significant milestone in cell death biology. The capacity of p53 to directly disrupt mitochondrial membranes reshapes our comprehension of apoptotic regulation and opens novel avenues for therapeutic innovation. While the nuances of this pathway await full elucidation, the dialogue sparked by the editorial expression of concern amplifies the dynamic and iterative nature of scientific progress. p53, once again, confirms its central position at the crossroads of life and death within the cell.

Subject of Research: p53’s mitochondrial translocation and its direct role in mitochondrial outer membrane permeabilization independent of Puma and Bax.

Article Title: Editorial Expression of Concern: p53’s mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity.

Article References: Wolff, S., Erster, S., Palacios, G. et al. Editorial Expression of Concern: p53’s mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res (2025). https://doi.org/10.1038/s41422-025-01129-0

Image Credits: AI Generated

Senescent cells, often immune to programmed cell death, become a significant concern in the context of cancer treatment. They arise from various stress factors, including chemotherapeutic agents and radiation therapy. While these interventions are designed to eradicate tumors, they inadvertently spawn cell populations that, while inactive in terms of proliferation, possess metabolic activity that could lead to adverse long-term health outcomes. A closer examination of the survival mechanisms that allow these cells to persist highlights a critical area of research that might improve therapeutic approaches for patients undergoing cancer treatment.

A common question arises: why do senescent cells exhibit such resilience? According to Professor Montero, the answer lies in the intricate interplay of biological mechanisms triggered during treatment. Chemotherapy and radiotherapy are not exclusively destructive; they can incite a cellular response leading to senescence. In this context, senescent cells become detrimental not only due to their survival but also because they can contribute to the re-establishment of tumors, effectively undermining the initial success of cancer therapies. This dual role of senescent cells underscores the necessity of understanding their biology in the quest for improved cancer treatment strategies.

The research team focused their efforts on elucidating the molecular factors that enable the dominance of senescent cells post-treatment. The BCL-2 family of proteins emerged as a crucial component of this investigation, as these proteins play a pivotal role in regulating cell death. This family includes both pro-apoptotic proteins, which promote cell death, and anti-apoptotic proteins, which inhibit it. The study explores the dynamics of these protein interactions and how they may be manipulated to foster successful elimination of senescent cells, thus enhancing recovery prospects for cancer patients.

As the study progressed, the researchers employed BH3 profiling, an advanced technique developed in the Dana-Farber Cancer Institute, to delve deeper into the interactions between BCL-2 family proteins and senescent cells. This profiling technique allows for precise evaluation of the apoptotic machinery at play, aiding in the identification of key players in the survival of these stubborn cells. The findings revealed that BCL-XL, an anti-apoptotic protein, exhibited increased presence and activity in senescent melanoma cells, revealing a crucial vulnerability that could be exploited for therapeutic gain.

In their quest for effective treatment modalities, the researchers identified compounds with senolytic activity, which specifically target and eliminate senescent cells. These compounds, including A-1331852 and navitoclax, may provide a practical path for researchers striving to improve patient outcomes. By exploiting the vulnerabilities identified in the BCL-XL protein, therapeutic strategies can potentially shift the balance from survival towards eradication of senescent cells. The hope is that by diminishing these problematic cells, the possibility of tumor recurrence could be significantly reduced.

Another intriguing facet of this research is the role of the HRK protein, which functions as a regulator of BCL-XL. The study found that levels of HRK protein decline during the induction of senescence, thereby freeing BCL-XL to carry out its protective role. The profound implications of these findings suggest that therapies that could maintain or enhance HRK levels might provide a two-fold benefit: promoting the apoptosis of senescent cells while simultaneously preventing their restorative influence on tumor recurrence.

This research opens new avenues for future studies aimed at translating these findings into clinical applications. While the study focuses on melanoma, the authors emphasize the potential for these molecular mechanisms to apply across a spectrum of cancer types. The next steps will involve assessing whether the insights gained from melanoma can be replicated in other cancers, such as lung or breast cancer. Understanding the universality of these mechanisms could lead to broad-spectrum strategies in the fight against multiple cancer manifestations.

Moreover, understanding the influence of BCL-2 family proteins in the aging process further extends the impact of this research beyond oncology. The role these proteins play in senescence may correlate with broader patterns of aging that affect various tissues and organs. This exploration could contribute valuable insights into age-related diseases, linking cancer biology with the fundamental processes of aging.

The researchers express optimism that the identification of key molecular interactions will catalyze the development of innovative therapies aimed at eliminating senescent cells, ultimately improving the therapeutic landscape for cancer patients. As they prepare for additional research studies, Montero and Alcon highlight the necessity of interdisciplinary collaboration and continued investigation into the molecular basis of senescence.

In summary, the findings from this study illuminate a critical aspect of cancer biology and provide a foundational understanding for further exploration into the toxic legacy left by cancer therapies. By shedding light on the survival mechanisms of senescent cells, this research holds promising implications for therapeutic innovations aimed at not only enhancing cancer recovery but also improving the quality of life for patients enduring the long-term effects of treatment.

Subject of Research: Cells
Article Title: HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
News Publication Date: 3-Dec-2024
Web References: Nature.com
References: doi:10.1038/s41418-024-01417-z
Image Credits: UNIVERSITY OF BARCELONA

Keywords: Senescence, BCL-2 Family Proteins, Cancer Therapies, Oncology, Cell Death, Melanoma.